Pharma · Private company
Genentech, Inc.
Track this companyFree. Adds Genentech, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs32From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline32
- EverolimusPhase 3 · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ExemestanePhase 3 · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 3 · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- GiredestrantPhase 3 · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- LHRH AgonistPhase 3 · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- TamoxifenPhase 3 · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- AlectinibPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- cBTKi MonotherapyPhase 2 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CobimetinibPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- EntrectinibPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- GDC-1261Phase 2 · Advanced Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- PralsetinibPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- SelnoflastPhase 2 · AtherosclerosisClinicalTrials.gov · fetched Nov 12, 2026
- VemurafenibPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 2 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 1 · Locally Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 1 · Locally Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- EnzelkitugPhase 1 · Locally Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- FaricimabPhase 1 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- GDC-9545Phase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- LHRH AgonistPhase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- PalbociclibPhase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Locally Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- RO7566802Phase 1 · Locally Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- RO7656594Phase 1 · Advanced Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- RO7823653Phase 1 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- LUCENTIS (Ranibizumab Injection)Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- OCR SCMultiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- PDS Implant With Ranibizumab 100 mg/mlNeovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaPHASE2 · NOT_YET_RECRUITING · started Apr 29, 2027ClinicalTrials.gov NCT07917832 · fetched Nov 12, 2026
- Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan TrialPHASE2 · NOT_YET_RECRUITING · started Mar 1, 2027ClinicalTrials.gov NCT07910435 · fetched Nov 12, 2026
- A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell LymphomaPHASE2 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07799220 · fetched Nov 12, 2026
- Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaPHASE2 · NOT_YET_RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07916389 · fetched Nov 12, 2026
- A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyPHASE4 · RECRUITING · started Sep 2, 2026ClinicalTrials.gov NCT07609719 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac EventsPHASE2 · RECRUITING · started Jun 5, 2026ClinicalTrials.gov NCT07448038 · fetched Nov 12, 2026
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate CancerPHASE1_PHASE2 · RECRUITING · started Apr 29, 2026ClinicalTrials.gov NCT07567846 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)PHASE1 · RECRUITING · started Apr 21, 2026ClinicalTrials.gov NCT07425522 · fetched Nov 12, 2026
- GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 30, 2025ClinicalTrials.gov NCT06522386 · fetched Nov 12, 2026
- A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell LymphomaPHASE2 · RECRUITING · started Jan 16, 2025ClinicalTrials.gov NCT06765317 · fetched Nov 12, 2026
- A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment PeriodPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 9, 2024ClinicalTrials.gov NCT06524375 · fetched Nov 12, 2026
- A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 15, 2024ClinicalTrials.gov NCT06096779 · fetched Nov 12, 2026
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaPHASE2 · RECRUITING · started May 7, 2024ClinicalTrials.gov NCT06213311 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 27, 2023ClinicalTrials.gov NCT06031441 · fetched Nov 12, 2026
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate CancerPHASE1 · RECRUITING · started May 2, 2023ClinicalTrials.gov NCT05800665 · fetched Nov 12, 2026
- Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular LymphomaPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 24, 2022ClinicalTrials.gov NCT05410418 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 20, 2022ClinicalTrials.gov NCT05581004 · fetched Nov 12, 2026
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)PHASE3 · ACTIVE_NOT_RECRUITING · started Aug 3, 2022ClinicalTrials.gov NCT05306340 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsPHASE2 · RECRUITING · started May 12, 2022ClinicalTrials.gov NCT05039619 · fetched Nov 12, 2026
- Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCCPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 19, 2022ClinicalTrials.gov NCT05085496 · fetched Nov 12, 2026
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)PHASE4 · ACTIVE_NOT_RECRUITING · started Dec 14, 2021ClinicalTrials.gov NCT04853251 · fetched Nov 12, 2026
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 6, 2020ClinicalTrials.gov NCT04302025 · fetched Nov 12, 2026
- Genetic Testing in Guiding Treatment for Patients With Brain MetastasesPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 17, 2019ClinicalTrials.gov NCT03994796 · fetched Nov 12, 2026
- A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 24, 2017ClinicalTrials.gov NCT03332797 · fetched Nov 12, 2026
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasPHASE2 · RECRUITING · started Sep 28, 2015ClinicalTrials.gov NCT02523014 · fetched Nov 12, 2026